Opportunistic etiological agents causing lung infections: emerging need to transform lung-targeted delivery
6 Options For Getting STD Treatment Online
CallOnDoc is another excellent option for receiving a prescription for an STI without any phone calls or video chats. Plus, the platform offers your sexual partner 50% off their treatment once they consent to it.
To get started, you'll fill out a form that takes approximately 10 minutes to complete. CallOnDoc reviews your symptoms and sends a prescription (if applicable) to your local pharmacy within 1 to 2 hours.
Pricing depends on which STIs you believe you may have — in fact, you get started by selecting the likely STI and filling out the relevant form. If you're not sure which STI you may have, select the "unsure" form option, which is $59.
This platform offers prescriptions for many STIs. They also offer HIV prevention medication and treatments for bacterial vaginosis (BV) and urinary tract infections (UTIs).
You can also get herpes treatment. However, keep in mind that there is no cure for herpes. While this platform can get you started with medication, you'll need consistent visits to a healthcare professional for continual management.
Finally, for some STIs, such as syphillis, you may need to get tested before a healthcare professional can prescribe medication.
CallOnDoc is available 7 days a week, including nights and holidays.
BioVersys Joins EU-Funded RespiriNTM Programme To Accelerate Development Of Its Broad-Spectrum Drug Candidates Against NTM Pulmonary Diseases
BASEL, Switzerland, Oct. 22, 2024 (GLOBE NEWSWIRE) --
BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria, announced today that it has joined the EU-funded RespiriNTM programme, an 8-year journey exploring multiple approaches to determine new targets for anti-mycobacterial compounds, define and optimize novel inhibitors and move these through the process of hit-to-lead up until the First-in-Human trials. BioVersys' in-house non-tubercular mycobacteria (NTM) project will have access to up to approximately €2 million in non-dilutive funding from the original IMI2 RespiriNTM grant of approximately €5.7 million, and to key capabilities of established consortium partners to develop novel candidates to address NTM pulmonary disease (NTM-PD).
NTM-PD is estimated to affect more than 86,000 people in the US according to the American Lung Association and antimicrobial resistance (AMR) is a major global health threat with currently available therapeutics becoming more and more obsolete due to AMR.1 This is of greatest concern when addressing NTM-PD, as chronic antibiotic treatments of 12-24 months required for these infections often lead to the development of antibiotic resistance. Due to the lack of effective treatment options, current cure rates for NTM-PD are as low as 30-50%.2 Particularly vulnerable to NTM-PD are people who suffer from structural airway diseases such as cystic fibrosis, COPD and bronchiectasis.
BioVersys' NTM program is derived from the company's proprietary Ansamycin Chemistry platform. The BioVersys' research team is developing a novel and highly potent broad-spectrum anti-NTM ansamycin, suitable for oral or inhalation therapy that is devoid of cross-resistance with other therapeutic classes. Since NTM-PD patients are often on multi-drug regimens, the company focuses on developing molecules that do not show any significant potential for drug-drug interactions.
Meindert H. Lamers, Associate Professor, Leiden University Medical Center & RespiriNTM Project Coordinator: "Working together with BioVersys on the RespiriNTM project is a unique opportunity. Their powerful ansamycin class of inhibitors have the potential to provide an effective and highly needed treatment option for NTM infections, which fits perfectly with the aims of the RespiriNTM project. BioVersys' strong drive to deliver a novel NTM antibiotic has invigorated the RespiriNTM project. Our collaboration to date has been very stimulating and I am very much looking forward to deepening our collaboration with BioVersys over the coming years."
Dr. Sergio Lociuro, Chief Scientific Officer of BioVersys: "Following on from the recent successes of TRIC-TB, we are very pleased to have the opportunity to join a second IMI2 JU funded programme, which is tackling another area of high unmet medical need. RespiriNTM is a strong consortium of many expert partners with valuable experience in the field of antimicrobial resistance. We aim to develop our broad-spectrum NTM candidates into effective treatments against these difficult to treat pulmonary diseases to positively impact patients' lives."
About RespiriNTMMycobacterium avium complex (MAC) and Mycobacterium abscessus subspecies (MAB) cause several hundreds of thousands of infections worldwide each year. Unlike the well know related species M. Tuberculosis, there are currently limited and poor treatment options to address these pathogens with significant levels of relapse and unacceptably high mortality rates, approaching 45%.3 Therefore, there is an urgent need for antibiotics that can treat the debilitating diseases that are caused by the Non-Tuberculous Mycobacteria (NTM), M. Avium complex and M. Abscessus. The RespiriNTM project aims to develop novel antibiotics that target the RNA transcription machinery that is required for protein production in the cell. Through this work we aim to develop desperately needed antibiotics that work against M. Avium and M. Abscessus that form an increasing threat to global health. RespiriNTM is part of the IMI AMR Accelerator Programme.
About non-tubercular mycobacteriaNon-tuberculous Mycobacteria (NTM) are ubiquitous environmental bacteria whose common clinical manifestation is pulmonary disease (NTM-PD) caused most frequently by Mycobacterium avium complex (MAC) and Mycobacterium abscessus subspecies (MAB).4 NTM-PD affects approximately 250,000 people per year, predominantly in North America and Asia.4 Treatment of NTM infections is challenging due to variable intrinsic bacterial susceptibility, acquired resistance to commonly used antimicrobial agents, length of therapy (at least 12 months) and adverse effects associated with current treatment options. Macrolide-based, triple drug regimens, plus aminoglycosides for chronic/relapsing infections5 are considered only moderately effective for treating MAC, whereas no therapy of predictable efficacy exists for the treatment of M. Abscessus, a pathogen associated with up to 50% mortality.6 People with predisposed conditions, including cystic fibrosis (CF), other lung diseases and immune-compromised patients are more easily colonised. Alarmingly, the incidence of NTM infections among people living with CF has increased from 3.3% to 22.6%, with MAB becoming a very prominent pathogen.7
Statements or views expressed in this release are of those of the respective organizations or persons and the IMI2 JU is not responsible for any use of the information contained herein.
The RespiriNTM project has received funding from the Innovative Health Initiative 2 Joint Undertaking (JU) under grant agreement No 853932. This Joined Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.
About the Innovative Medicines InitiativeThe Innovative Medicines Initiative (IMI) IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It was set up to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently-needed new treatments in diverse areas. IMI projects are now managed by the Innovative Health Initiative (IHI), which builds on the successes of IMI and is a cross-sectoral public-private partnership involving a wider range of health industries.
About BioVersysBioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria. Derived from the company's two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company's most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 2), and tuberculosis (alpibectir, Phase 2a, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland.
BioVersys contactSylvia Mundt, Tel. +41 61 633 22 50; Mail: IR@bioversys.Comwww.Bioversys.Com
https://twitter.Com/Bioversyshttps://www.Linkedin.Com/company/bioversys-ag
1 Lancet, Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis, VOLUME 399, ISSUE 10325, P629-655, FEBRUARY 12, 20222 Wang et al., 2022; Novosad et al., 2017; Lee et al., 2021; Mourad et al., 20213 The Impact of Nontuberculous Mycobacteria Species on Mortality in Patients with Nontuberculous Mycobacterial Lung Disease. Wang et al, 2022, Frontiers in Microbiology. Doi:10.3389/fmicb.2022.9092744 Hamed KA & G. Tillotson "A narrative review of nontuberculous mycobacterial pulmonary disease: microbiology, epidemiology, diagnosis, and management challenges" Ex. Rev. Resp. Med. (2023), 17 (11), 973 - 988 https://doi.Org/10.1080/17476348.2023.22831355 Daley CL et al. "Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline" Eur. Resp. J. (2020), 56, 2000535; https://doi.Org/10.1183/13993003.00535-2020; Griffith DE et al. "An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases" Am. J. Respir. Crit. Care Med. (2007), 175, 367–416; https://doi.Org/10.1164/rccm.200604-571ST6 Jhun BW et al. "Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study" Eur. Resp. J. (2020), 55, 1900798; https://doi.Org/10.1183/13993003.00798-20197 Degiacomi G. Et al. "Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients" Int. J. Mol. Sci. (2019), 20, 5868; doi: 10.3390/ijms20235868
Understanding Treatment-Resistant Bipolar Depression
In treatment-resistant bipolar depression, symptoms don't respond to standard treatments, making management difficult. Alternative therapy options and self-help techniques may help you cope.
Despite various treatment options, some individuals with bipolar disorder continue to experience debilitating symptoms, especially during depressive episodes.
Let's take a look at what defines treatment-resistant bipolar disorder, its symptoms, and various strategies to manage this complex form of the illness.
Treatment-resistant bipolar disorder occurs when symptoms — such as mania or depression — do not respond adequately to standard treatments like:
Depressive episodes are especially difficult to treat, with about one-quarter of people with bipolar disorder experiencing treatment-resistant bipolar depression. This typically means they don't see improvement even after trying at least two different medications.
Symptoms of treatment-resistant bipolar depression are similar to symptoms of bipolar depression that are managed with first-line treatment options.
However, if your symptoms persist despite treatment with standard medications, you may experience:
While challenging, it is possible to cope with treatment-resistant bipolar depression.
Consider trying various non-first-line medications, like ketamine or modafinil. Here are some options to consider:
Medically supervised ketamine therapy
Ketamine is a drug originally used as an anesthetic but is now also used to treat bipolar depression.
Research from 2022 suggests that ketamine may be particularly helpful in individuals with treatment-resistant bipolar depression.
It helps by altering the brain's glutamate system, which can quickly improve mood. Since its effects may be short-lived, it's often combined with other treatments for more lasting results. Combining ketamine with psychotherapy may extend its benefits even further.
Lurasidone
Lurasidone is an atypical antipsychotic medication. It's typically used when other treatments have not been effective or when there are specific reasons to choose it over other options.
One study found that 20 to 60 milligrams per day of lurasidone significantly reduced depressive symptoms and improved functioning compared to placebo.
Modafinil
Modafinil is a medication commonly used to promote wakefulness in conditions like narcolepsy and obstructive sleep apnea. More recently, it has been explored as an adjunctive treatment for bipolar 1 depression.
Some evidence indicates that modafinil can significantly improve depressive symptoms and functioning in people with bipolar depression, particularly those experiencing severe hypersomnia (excessive sleepiness). It's considered a second-line therapy by Canadian guidelines for treating bipolar 1 depression.
However, there are concerns about modafinil potentially triggering manic episodes or psychosis in people with bipolar disorder or other psychiatric conditions.
Advanced therapies
Alongside medication, adopting lifestyle changes like exercise and using immediate coping strategies, such as taking a cold shower, may also help manage your symptoms.
In addition to the therapies and medication options available for treatment-resistant bipolar disorder, you may also consider trying:
Cold water immersion
Short bursts of cold water, such as cold showers or immersion, can activate the body's stress response, releasing endorphins and boosting energy, which may temporarily improve mood.
A study involving 42 college students who underwent cold-water immersion showed significant improvements in mood, including:
In contrast, the control group, who didn't experience cold-water immersion, showed little to no change in mood.
Regular exercise
Physical activity, particularly aerobic exercise, can significantly improve mood by releasing endorphins, reducing anxiety, and improving sleep quality.
Outdoor exercise is especially beneficial due to the added benefits of sunlight exposure.
A review of 218 studies showed that exercise, especially walking or jogging, yoga, and strength training, can significantly reduce depression. All exercises worked better than usual care or placebo, with more intense exercises showing greater benefits.
Mindfulness and meditation
Practicing mindfulness or guided meditation can help calm the mind, reduce anxiety, and improve emotional regulation. In turn, this can help you manage the stress and mood fluctuations associated with bipolar depression.
Those who attended all meditation sessions and practiced regularly experienced the most benefits. Meditation helped alleviate feelings of guilt, depressed mood, and hopelessness.
Supplements
Some supplements may help manage bipolar depression when used alongside traditional treatments, though they should always be discussed with a healthcare professional.
Here are a few that have shown potential:
Spicy foods
Foods containing capsaicin, the compound that makes spicy food hot, can trigger the release of endorphins and serotonin, providing a natural mood lift and temporarily reducing stress.
Animal research suggests that capsaicin may alleviate symptoms of depression and Parkinson's disease. It may also reduce neurodegeneration and memory loss in Alzheimer's and improve outcomes in stroke models.
Support system
A strong support system offers both emotional and practical benefits. Your support system may include:
Loved ones can assist with everyday tasks that may become overwhelming during depressive episodes, such as household chores, appointments, and medication management.
In addition, therapy and support groups can provide safe spaces for sharing experiences, learning coping strategies, and connecting with others who face similar challenges.
Treatment-resistant bipolar disorder occurs when symptoms of bipolar disorder, particularly depression, don't respond well to standard treatments, even after trying multiple medications or therapies.
While it can be challenging, emerging treatments and strategies offer hope. With persistence and support, you can find a path toward managing your symptoms and improving your quality of life.
Comments
Post a Comment